Engineered amorphous silica nanoparticles, known as Cornell Prime dots (C’ dots), are effectively killing aggressive prostate tumors in preclinical models while simultaneously activating the body’s immune response, according to a study published June 15 in Cancer Research. Researchers at Weill Cornell Medicine and the Cornell Duffield College of Engineering found that these particles, which were originally designed for medical imaging, trigger a self-destruct mechanism in tumor cells known as ferroptosis and successfully convert “cold,” inactive immune environments into “hot,” responsive ones.
How do silica nanoparticles kill prostate cancer cells?
The C’ dots function by transporting reactive iron ions into tumor cells, which triggers a process called ferroptosis, according to senior author Dr. Michelle Bradbury of Weill Cornell Medicine. This mechanism causes the overwhelming oxidation of fat-related molecules within cell membranes, leading to their degradation. Unlike traditional chemotherapy, which often damages healthy tissue, these silica-based particles are targeted to prostate tumor cells using a molecule that binds to the PSMA surface protein. Co-corresponding author Ulrich Wiesner of Cornell University notes that the particles appear to avoid healthy tissues entirely, even when they briefly concentrate in organs like the spleen.
What is the impact on immunotherapy?
The particles significantly enhance the efficacy of existing cancer treatments by remodeling the tumor microenvironment, according to Dr. Jedd Wolchok, director of the Parker Institute for Cancer Immunotherapy at Weill Cornell Medicine. In mouse models, the combination of C’ dots and immune checkpoint blockade resulted in complete or near-complete tumor remission in 40% of cases. When researchers added a third treatment—a CSF-1R blockade targeting tumor-associated macrophages—the rate of complete remission rose to 50%. This suggests that silica particles could help overcome the resistance often seen in prostate cancer immunotherapies.
How does this compare to traditional treatments?
While traditional oncological approaches often focus on one pathway—either direct cell death or immune stimulation—the C’ dots achieve both simultaneously. The following table highlights the observed outcomes in the study’s survival experiments:
| Treatment Method | Survival Outcome |
|---|---|
| No treatment | Baseline |
| C’ dots alone | Moderate extension |
| C’ dots + Checkpoint blockade | 4/10 complete remissions |
| C’ dots + Checkpoint + CSF-1R blockade | 5/10 complete remissions |
What are the next steps for clinical trials?
The research team is currently focusing on evaluating the safety and efficacy of these particles for future human clinical trials. Because the particles were already developed for medical imaging and have undergone advanced-phase safety testing in that context, the transition to therapeutic use may be more streamlined than for entirely new drug compounds. Dr. Bradbury and Dr. Wiesner have secured patents related to the technology, as reported in the Cancer Research study.
If you are interested in the latest advancements in nanomedicine, keep an eye on the American Association for Cancer Research (AACR) journals for updates on the transition of C’ dots from laboratory models to human trials.
Frequently Asked Questions
Are silica nanoparticles toxic to healthy cells?
No. According to the study, researchers observed no signs of toxicity in healthy tissues, including the spleen, even when the particles were present.
What is ferroptosis?
Ferroptosis is a form of cell death driven by the iron-dependent oxidation of lipids, which degrades cell membranes. The C’ dots encourage this process specifically within tumor cells.
Can this treatment be used for other cancers?
The current study focused on aggressive prostate cancer models. However, the researchers are continuing to explore the particles’ ability to modulate immune and metabolic pathways, which could have implications for other solid tumors.
Have questions about this research or want to stay updated on the latest breakthroughs in oncology? Subscribe to our newsletter or leave a comment below to join the discussion.
Related reading